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Ataxia-Telangiectasia is a rare multisystem autosomal recessive disorder [OMIM 208900], caused by mutations in
Ataxia-Telangiectasia Mutated gene. It is characterized by neurological, immunological and cutaneous involvement.
Granulomas have been previously reported in Ataxia-Telangiectasia patients, even if acne rosacea has not been described.
We report a case of a young Ataxia-Telangiectasia patient with a severe immunological and neurological involvement,
who developed granulomatous skin lesions diagnosed by skin biopsy as acne rosacea. Considering the severe clinical
picture and the lack of improvement to multiple topic and systemic therapies, treatment with Isotretinoin was started
and the skin lesions disappeared after five months. However the therapy was stopped due to drug-hepatotoxicity.
Systemic treatment with Isotretinoin should be carefully considered in patient with Ataxia-Telangiectasia for the
treatment of multi-drug resistant acne rosacea, however its toxicity may limit long-term use and the risk/benefit
ratio of the treatment should be evaluated.
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Ataxia-Telangiectasia (A-T) [OMIM 208900] is a rare
multisystem autosomal recessive disorder, caused by mu-
tations in ATM (Ataxia-Telangiectasia Mutated) gene. It
is characterized by cerebellar ataxia, oculocutaneous telan-
giectasias, oculomotor apraxia, variable immunodeficiency
with recurrent infections, radiosensitivity and predispos-
ition to malignancies. Cutaneous involvement usually
includes telangiectasia, cafè-au-lait macules, hyper and
hypopigmented macules and progeroid changes. Eczema
and acanthosis nigricans may also be present, as well as
vitiligo and granulomas [1].
Diagnosis is suggested by the clinical aspects, in ac-
cording with elevated serum levels of alfa-fetoprotein
and confirmed by detection of ATM protein expression
by western blot analysis and identification of the gene
mutations.* Correspondence: nicolcant@hotmail.it
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unless otherwise stated.Cutaneous granulomatosis with unknown etiology, not
related to infections, occur rarely in patients with primary
immunodeficiencies (PIDs) [2]. These granulomas have
been previously described in CVID, CGD, SCID, X- hypo-
gammaglobulinemia, Wiskott-Aldrich syndrome and in
A-T [2,3]. Particularly acne rosacea has not been described
before in patients with A-T. We report a case of multi-
drugs resistant acne rosacea in ataxia-telangiectasia, suc-
cessful treated with Isotretinoin.Case report
A 15 years old girl, born from healthy Caucasian non-
consanguineous parents, referred to our center at the
age of 2 years with a history of failure to thrive and
ataxic gate. The neurological picture was characterized
by trunk and head ataxia, oculomotor apraxia, hypotonus,
dysarthria, dysmetria and intention tremor. Physical exam-
ination revealed oculocutaneous telangiectasias, cafè-au-lait
macules and striae rubrae. She suffered from recurrent in-
fections, particularly by respiratory tracts infections and
repeated episodes of fever of unknown origin. During fol-
low up she developed chronic EBV infection that lead toral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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at a weekly dose of 375 mg/m2 for 2 weeks. Immuno-
logical studies reveled a combined immunodeficiency,
characterized by low level of serum IgA; non protective
specific antibodies response against tetanus, after vaccin-
ation; T and B lymphopenia, associated with reduced naïveTable 1 Immunological data of the patients showing
decrease level of IgA, T and B lymphopenia; reduced
naïve T subsets (CD4RA,CD8RA); low lymphocyte
proliferation to PHA; nonprotective specific antibodies
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CD4+ and CD8+ TCR analysis (Spectratyping)
CD4+ SKEWED 43%
CD8+ SKEWED 100%T subsets; low lymphocyte proliferation to PHA and
skewed T Cell Receptor repertoire (Table 1). On the basis
of the infections history and immunological assessment,
intravenous immunoglobulin replacement therapy (IVIG)
was started. Diagnosis of Ataxia-Telangiectasia (A-T)
was confirmed by molecular analysis of ATM gene and
by the evidence of ATM protein absence by western
blot analysis.
At the age of 10 years the girl developed papules, pus-
tules and granulomatous skin lesions with centrofacial
distribution; a diagnosis of herpetic infection in im-
munocompromised patient has been suggested due to
the presence of vesicular-pustular lesions with central
umbilication. Treatment with acyclovir was started, in
addition to systemic and local antibiotic therapy, but no
improvement was observed. Because of the persistence
and spreading of cutaneous lesions (Figure 1) and the
negative result of DNA-HSV on the peripheral blood, a
skin biopsy was performed and the histological study re-
vealed a granulomatous inflammatory process rich in ep-
ithelioid histiocytes with a few multinucleated giant cells
(Figure 2a-d). Stains for pathogens (Ziehl-Neelsen, PAS,
Giemsa) were negative. The diagnosis of granulomatous
acne rosacea was made. Rosacea fulminans was excluded
because of the long lasting course characterized by a
slow formation of new cutaneous lesions without drain-
ing sinuses. Moreover, on histology granulomas were
striking while papillary dermis edema and deep dermal
fibrosis were minimal. Therefore, the patient underwent
oral and topical metronidazole treatment, but a signifi-
cant worsening of the skin lesions with bacterial super-
infection rapidly followed a slight improvement. Topical
clindamycin was added to the ongoing therapy, while
metronidazole was stopped due to detection of hyper-
transaminasemia at the blood tests. An assay with top-
ical Pimecrolimus and systemic and topical Tetracycline
was attempted, but, after a short period of improvement,
a new worsening of the skin lesions occurred.
Considering the severe clinical picture and the lack of
improvement to multiple therapies, systemic treatment
with Isotretinoin (0,5 mg/kg/die) was started. The lesionsFigure 1 Picture of the patient showing the presence of
erythematous, papular-nodular lesions and telangiectasias
on the face; ulceronecrotic lesions on the nasal pyramid with
destructive effect on the wings of the nose. Some scars are
evident as result of the disease.
Figure 2 Histological images of skin biopsy revealing a granulomatous inflammatory process. The microphotograph shows a severely
damaged epidermis due to a dense inflammatory process obliterating the entire dermis, mainly composed of histiocytes with an epithelioid
appearance and lymphocytes arranged in a granulomatous pattern (a). The immunostaining for CD68 shows positivity in the vast majotity of
infiltrating cells (b). A few multinucleated giant cell of Langhans type are present (c, insert) which are positive for CD 68 (d, insert). a) HE 10 x;
b) Immunostaining 20 x; c) HE 40 x; d) Immunostaining 40 x.
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disappeared after five months (Figure 3), with residual
pitted scars as documented histologically in a biopsy
obtained from to same area (Figure 4). The treatment
was continued for six months and then tapered, but a
new worsening was observed. Therefore the therapy
was resumed and stopped after five months due to
drug-hepatotoxicity, with early relapse of skin lesions and
progressive destruction of nose’s cartilage.
Cutaneous involvement is common in Ataxia-
Telangectasia and usually it presents with cutaneous
telangiectasia, skin atrophy, café-au-lait spots and prema-
ture graying. Cutaneous granulomas have occasionally
been reported in patients with A-T [3-11], whereas acne
rosacea has not been previously described in patients with
A-T.Figure 3 Picture of the patient after five months of systemic
treatment with Isotretinoin (0,5 mg/kg/die): the erythematous,
papular-nodular and ulceronectrotic lesions disappeared with
some residual pitted scars.Acne rosacea is a chronic inflammatory disorder, charac-
terized by centrofacial erythema, telangiectasias, papules,
pustule and occasionally nodules or cysts on the forehead,
cheek and nose. Rosacea can be classified in four different
subtypes: erythemato-teleangiectatic, papulopustular, phy-
matous and ocular [12].
Cutaneous manifestations in immunocompromised pa-
tients have usually an atypical onset with chronic evolu-
tion and require more aggressive and prolonged therapy
than non-immunocompromised one.Figure 4 Post-isotretinoin skin biopsy showing mild changes:
slight hyperkeratosis, focal parakeratosis, acanthosis. The
dermis shows thickened collagen bundles, telangectasias and sparse
or periadnexal lymphocytes. HE 4 x.
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in some patients with PIDs; other have described the
development and persistence of cutaneous granulomas in
patients on intravenous immunoglobulin replacement
therapy [2,3]. Similarly, topic and systemic steroids in
conjunction with antibiotics had no effects. Noteworthy,
the cutaneous disease control in some PID’s patients
has been obtained only after hematopoietic stem cells
transplantation [2].
The conventional therapeutic regimens for acne ros-
acea, in non-immunocompromised patients, include
topical and oral metronidazol, topical azelaid acid and
oral doxycycline, in addition to adequate skin care [13].
Further interesting therapy option could be Isotretinoin,
used off-label because of the lack of evidence-based
data [14].
Isotretinoin is a synthetic retinoid derived from retinol,
that is primary use orally for the treatment of severe, re-
fractory, inflammatory acne. In literature is reported the
efficacy of Isotretionin treatment, in patient affected by
acne rosacea, at the dosage of 0.5 mg/kg/day. In particular
its use is indicated for those patients who had experienced
insufficient or transient effects with conventional topical
and systemic therapies. The efficacy of Isotretinoin in
rosacea is probably related to its anti-inflammatory, an-
tioxidative, antiangiogenic, and antifibrotic properties,
in addition to its ability to reduce the size of sebaceous
glands [15].
Our patient is immunocompromised, she received mul-
tiple oral and topical treatments (steroids, mupirocin,
metronidazole, tetracycline, clindamycin and pimecroli-
mus), without any improvement, whereas the lesions dis-
appeared after five months of Isotretinoin, with residual
pitted scars. In spite of its anti-inflammatory and immu-
nomodulator properties, we did not observe an impair-
ment of immune responses in our child, but on the other
side a severe hepatotoxicity was detected and the treat-
ment was stopped.Conclusion
Due to our experience, the choice of Isotretinoin should
be carefully considered in patients with A-T for the
treatment of acne rosacea resistant to conventional
therapies, however its toxicity may limit long-term use
and the risk/benefit ratio of the treatment should be
evaluated.Consent
Written informed consent was obtained from the parents
of the patient for publication of this Case report and any
accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.Abbreviations
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